Trubion Pharmaceuticals
Inc. (Nasdaq: TRBN) announced that its collaboration partner Wyeth
Pharmaceuticals, a division of Wyeth (NYSE: WYE), has initiated a Phase 1
clinical trial of SBI-087, a next-generation drug candidate for the
treatment of rheumatoid arthritis (RA). In collaboration with Trubion,
Wyeth Pharmaceuticals is developing SBI-087 and other CD20-directed
products. SBI-087 for RA builds on Trubion and Wyeth's clinical experience
with Trubion's lead compound, TRU-015, and is based on Trubion's Small
Modular ImmunoPharmaceutical (SMIP(TM)) technology.
The Phase 1 SBI-087 dose escalation clinical trial is designed to
evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of
a single dose of SBI-087 in patients with RA. Preclinical research suggests
that SBI-087, a fully humanized CD20-directed SMIP, has enhanced potency in
B-cell depletion in vivo compared with Rituxan. This Phase 1 trial is
designed to enroll patients who meet the criteria for RA with Functional
Class I, II or III, and who have been diagnosed with RA more than six
months prior to the study with onset of RA after the age of 16.
With SBI-087, Trubion's pipeline now includes two differentiated
compounds under development for the treatment of autoimmune and
inflammatory diseases: TRU-015 and SBI-087. Trubion and Wyeth are
leveraging Trubion's SMIP(TM) technology to create a portfolio of product
candidates with customized mechanisms of action in an effort to optimize
patient safety, efficacy and convenience.
"Initiation of the SBI-087 Phase 1 clinical trial marks an important
milestone in advancing our pipeline through our collaboration with Wyeth,"
said Peter Thompson, M.D., FACP, president, CEO and chairman of Trubion.
"We believe SBI-087 and TRU-015 together will play an important role in
improving patient care and helping us establish category leadership in
autoimmune and inflammatory disease markets."
About Trubion
Trubion is a biopharmaceutical company that is creating a pipeline of
novel protein therapeutic product candidates to treat autoimmune and
inflammatory diseases and cancer. The company's mission is to develop a
variety of first-in-class and best-in-class product candidates, customized
for optimal safety, efficacy, and convenience that it believes may offer
improved patient experiences. Trubion's current product candidates are
novel single- chain protein, or SMIP(TM), therapeutics, and are designed
using its custom drug assembly technology. Trubion's product pipeline
includes CD20-directed candidates such as TRU-015 and SBI-087 for
autoimmune and inflammatory diseases, developed under the company's Wyeth
collaboration. Trubion's proprietary product candidate, TRU-016, is a novel
CD37-targeted therapy for the treatment of B-cell malignancies currently in
Phase 1/2 clinical evaluation. In addition to Trubion's current product
candidates, the company is also developing additional alliance and
proprietary product candidates that build on its product development
experience. More information is available in the investors section of
Trubion's website: investors.trubion.
Forward Looking Statements
Certain statements in this release may constitute "forward-looking
statements" within the meaning of Section 21E of the Securities Exchange
Act of 1934 and Section 27A of the Securities Act of 1933. These statements
include, but are not limited to, those related to the company's future
clinical development programs and the timing thereof, the company's
expected financial and operating results, future clinical development
plans, the details of the clinical trials and the results and timing
thereof, and the timing of regulatory applications and action. These
statements are based on current expectations and assumptions regarding
future events and business performance and involve certain risks and
uncertainties that could cause actual results to differ materially. These
risks include, but are not limited to, risks associated with the company's
Wyeth collaboration, including Wyeth's control over development timelines,
the risks that the Company is unable to advance its clinical development
programs and regulatory applications and action at the rate it expects, the
risk that the Company does not achieve the financial and operating results
it expects and such other risks as identified in the company's quarterly
report on Form 10-K for the period ended December 31, 2007, and from time
to time in other reports filed by Trubion with the U.S. Securities and
Exchange Commission. These reports are available on the Investors page of
the company's corporate Web site at trubion. Trubion
undertakes no duty to update any forward-looking statement to conform the
statement to actual results or changes in the company's expectations.
Trubion Pharmaceuticals Inc.
trubion
View drug information on Rituxan.